Peter Piot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Piot has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ana Wheelock
Faculty of Medicine, Imperial College London, London, United Kingdom
1 shared publication - Andreas Benedikt Eisingerich
Imperial College Business School, London, UK
1 shared publication - Blair S Hanewall
Bill & Melinda Gates Foundation, Seattle, Washington, USA
1 shared publication - Carl W. Dieffenbach
Division of AIDS National Institute of Allergy and Infectious Diseases National Institutes of Health Bethesda Maryland USA
1 shared publication - Catherine Hankins
Amsterdam Institute for Global Health and Development (AIGHD), Department of Global Health, University of Amsterdam, Amsterdam, the Netherlands
1 shared publication - Gabriela B. Gomez
Amsterdam Institute for Global Health and Development and Department of Global Health, Academic Medical Center, University of Amsterdam, Trinity Building C, Pietersbergweg 17, Amsterdam, 1105 BM, The Netherlands.
1 shared publication
Latest Publications
- Open Access
- 1 February 2010
- Published by BMJ in Sexually Transmitted Infections
- Vol. 86 (Suppl 1) , i1-i2
Setting new standards for targeted HIV prevention: the Avahan initiative in India
- 1 February 2010
- Published by BMJ in Sexually Transmitted Infections
- Vol. 86 (Suppl 1) , i1-i2
Open AccessSetting new standards for targeted HIV prevention: the Avahan initiative in India
- Open Access
- 1 January 2010
- Published by Wiley in Journal of the International AIDS Society
- Vol. 13 (1) , 24
Planning for pre‐exposure prophylaxis to prevent HIV transmission: challenges and opportunities
There are currently several ongoing or planned trials evaluating the efficacy of pre‐exposure prophylaxis (PrEP) as a preventative approach to reducing the transmission of HIV. PrEP may prove ineffective, demonstrate partial efficacy, or show high efficacy and have the potential to reduce HIV infection in a significant way. However, in addition to the trial results, it is important that issues related to delivery, implementation and further research are also discussed. As a part of the ongoing discussion, in June 2009, the Bill & Melinda Gates Foundation sponsored a Planning for PrEP conference with stakeholders to review expected trial results, outline responsible educational approaches, and develop potential delivery and implementation strategies. The conference reinforced the need for continued and sustained dialogue to identify where PrEP implementation may fit best within an integrated HIV prevention package. This paper identifies the key action points that emerged from the Planning for PrEP meeting.
- 1 January 2010
- Published by Wiley in Journal of the International AIDS Society
- Vol. 13 (1) , 24
Open AccessPlanning for pre‐exposure prophylaxis to prevent HIV transmission: challenges and opportunities
There are currently several ongoing or planned trials evaluating the efficacy of pre‐exposure prophylaxis (PrEP) as a preventative approach to reducing the transmission of HIV. PrEP may prove ineffective, demonstrate partial efficacy, or show high efficacy and have the potential to reduce HIV infection in a significant way. However, in addition to the trial results, it is important that issues related to delivery, implementation and further research are also discussed. As a part of the ongoing discussion, in June 2009, the Bill & Melinda Gates Foundation sponsored a Planning for PrEP conference with stakeholders to review expected trial results, outline responsible educational approaches, and develop potential delivery and implementation strategies. The conference reinforced the need for continued and sustained dialogue to identify where PrEP implementation may fit best within an integrated HIV prevention package. This paper identifies the key action points that emerged from the Planning for PrEP meeting.